Press Releases Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:58 2024-05-06 am EDT			5-day change	1st Jan Change
2,004 ^DKK	-2.77%		+1.73%	-7.01%

May. 03	GENMAB : A good start to 2024; guidance unchanged
May. 03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Transactions in Connection with Share Buy-back Program	May. 06	GL
Genmab A/S : Investor Presentation - May 2024	May. 02	PU
Genmab A/S : Interim Report for the First Quarter of 2024	May. 02	PU
Genmab A/S : First Quarter 2024 Financial Results Presentation	May. 02	PU
Genmab Announces Financial Results for the First Quarter of 2024	May. 02	GL
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 29	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 22	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 22	AQ
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024	Apr. 16	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 15	GL
Transactions in Connection with Share Buy-back Program	Apr. 08	GL
ADC oncology acquisition to address solid tumours	Apr. 03	AQ
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	Apr. 03	BU
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	Apr. 03	GL
Transactions in Connection with Share Buy-back Program	Apr. 02	GL
Transactions in Connection with Share Buy-back Program	Mar. 25	GL
Genmab A/S : has published its Articles of Association	Mar. 21	PU
Completion of share buy-back program	Mar. 18	GL
Genmab Announces Initiation of Share Buy-Back Program	Mar. 15	GL

No results for this search

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT